We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Modulation of thioacetamide-induced liver fibrosis/cirrhosis by sildenafil treatment.
- Authors
Said, Eman; Said, Shehta A.; Gameil, Nariman M.; Ammar, Elsayed M.
- Abstract
Sildenafil citrate is a phosphodiesterase-5 inhibitor, approved for the treatment of erectile dysfunction. It enhances nitric-oxide-induced vasodilatation and it promotes angiogenesis. A relationship between angiogenesis and hepatic fibrosis has long been speculated, where the 2 are believed to progress together. In this study, the ability of sildenafil (10 mg·(kg body mass)-1, orally, once daily) to prevent and also reverse liver fibrosis/cirrhosis experimentally induced by thioacetamide injection (200 mg·kg-1, intraperitoneal (i.p.), 3 times·week-1) in male Sprague-Dawley rats has been investigated. Sildenafil administration, either to prevent or to reverse liver fibrosis/cirrhosis significantly improved the estimated hepatic functions, reduced hepatic hydroxyproline and, in turn, hepatic collagen content, as well as reducing serum levels of the pro-fibrogenic mediator transforming growth factor β1. In co-ordination with such improvement, fibrosis grades declined and fibrosis retracted. Herein, the observed results provide evidence for the potential therapeutic efficacy of sildenafil as an antifibrotic agent.
- Subjects
THIOACETAMIDE; FIBROSIS; IMPOTENCE; CIRRHOSIS of the liver; SILDENAFIL; PHOSPHODIESTERASE-5 inhibitors
- Publication
Canadian Journal of Physiology & Pharmacology, 2013, Vol 91, Issue 12, p1055
- ISSN
0008-4212
- Publication type
Article
- DOI
10.1139/cjpp-2013-0181